Oxford Spin-Out Just Raised $300M: What It Means for EU Biotech

Jan de Vries · 2026-10-16

OMass Therapeutics, a UK biotech spun out of Oxford, just closed an oversubscribed $300 million (€275 million) Series C round. That's a big deal for a company developing small-molecule drugs against tricky targets. But it's also a signal: European therapeutics funding is heating up in 2026. ### The Deal Details The round was co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings. They were joined by Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences. And every existing investor jumped back in, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford. That kind of backing tells you something about confidence in the science. ### What OMass Does Founded in 2016, OMass is a spin-out from Professor Dame Carol Robinson's lab at the University of Oxford. They're translating native mass spectrometry research into novel small-molecule therapeutics against targets that have historically been hard to drug. Their proprietary OdyssION platform combines next-generation native mass spectrometry, novel biochemistry techniques, and custom chemistry to interrogate drug targets within their native ecosystems. In plain English: they can study proteins in their natural environment, giving them cell-system fidelity with cell-free precision. ### Why This Round Matters OMass' Series C comes amid a wave of significant European therapeutics funding rounds in 2026. Here's a quick look at the landscape: - France's Bionyra Pharma secured €143 million ($156 million) for inflammatory diseases. - Denmark's Breye Therapeutics raised €67.5 million ($74 million) for its oral small-molecule pipeline, also co-led by Novo Holdings. - In the UK, Cambridge-based STORM Therapeutics secured €47.5 million ($52 million), Microbiotica raised €42 million ($46 million), Glasgow-based Mironid received €39.9 million ($43.5 million), and London-based Alchemab Therapeutics secured €29.3 million ($32 million). - The Netherlands' Laigo Bio added €5.5 million ($6 million). Together, these announcements represent about €374.7 million ($409 million) in newly reported financing during 2026. When you include OMass' round, that number jumps to €649.7 million ($709 million). That's a lot of capital flowing into European biotech. > "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow," says Ros Deegan, CEO of OMass Therapeutics. "We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology into the clinic." ### What's Next for OMass The proceeds will support the advancement of OMS1620, a potential best-in-class MC2 receptor antagonist, through Phase 2 clinical development in congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. OMS1620 has been designed to increase receptor residency time and maintain a durable effect. If it works, it could be a meaningful improvement for patients with these conditions. Evan Greif, Principal at Bain Capital Life Sciences, added: "OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs. We see meaningful potential for OMS1620 to improve the treatment for patients with CAH." Max Klement, Partner at Novo Holdings, echoed that sentiment: "Each of these candidates has the potential to address substantial unmet patient needs in their respective areas of endocrinology and immunology." ### The Bigger Picture For anyone following EU Inc news or European startup incorporation, this round is a reminder that Europe can produce and fund world-class biotech. The UK, in particular, continues to spin out cutting-edge science from its universities. And with investors like Bain, Novo Holdings, and Forbion leading the charge, there's plenty of dry powder for the right opportunities. If you're building in this space, the message is clear: the capital is there for breakthrough science.